

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/591,092
Filing Date	08-29-2006
First Named Inventor	Kirk Knowlton
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	041673-0206

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	5,571,698	November 5, 1996	Ladner et al.	
	A2	6,057,098	May 2, 2000	Buechler et al.	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A3	Cabily, et al. "Generation of Antibody Activity from Immunoglobulin Polypeptide Chains Produced in Escherichia Coli", <i>Proc. Natl. Acad. Sci. USA</i> , 81:3273, 1984	
	A4	Cwirla et al., "Peptides on Phage: A vast library of peptides for identifying ligands", <i>Proc. Natl. Acad. Sci. USA</i> 87, 6378-82, 1990	
	A5	Devlin et al., "Random Peptide Libraries: A Source of Specific Protein Binding Molecules", <i>Science</i> 249, 404-6, 1990	
	A6	Feldman and McNamara, "Myocarditis", <i>New Engl. J. Med.</i> , 343:1388-1398, at 1393 (2000)	

Examiner
Signature

/D. Jones/

Date

Considered

11/25/09

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.

DLMR_298797.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/591,092
Filing Date	08-29-2006
First Named Inventor	Kirk Knowlton
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	041673-0206

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	# ⁶
	A7	Fujiwara et al., "Synthesis of Human C-Type Natriuretic Peptide 22 Using Chlorotriyl Resin and Tetrafluoroboric Acid Deprotection", Chem. Pharm. Bull. (Tokyo) 44: 1326-31, 1996	
	A8	Huse, et al., "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda", Science, 246:1275-1281, 1989	
	A9	Huse et al., "Application of a Filamentous Phage pVIII Fusion Protein system Suitable for Efficient Production, Screening, and Mutagenesis of F(ab) Antibody Fragments", J. Immunol. 149, 3914-3920 (1992)	
	A10	Ishiwata, et al., "Studies of 18F-labeled pyrimidines", Eur.J.Nucl.Med., 9:185-189, 1984	
	A11	Keough, et al., "An Improved Method For Synthesis and Purification of 125I or 131I labeled Carrier-Free 5- IODO-1'-Deoxyuridine", J.Labeled Compound Radiopharm., 14:83-90, 1978	
	A12	Kiso et al., "Solution-Phase Synthesis of Porcine Brain Natriuretic Peptide (pBNP) Using S-Triethylacetamido-methylcystein", Chem. Pharm. Bull. (Tokyo) 38: 1192-99, 1990	
	A13	Kubota, et al., "Differential Diagnosis of AH109A Tumor and Inflammation by Radioscintigraphy with L-[Methyl-11C] methionine", Jpn.J.Cancer Res., 80:778-782, 1989	
	A14	Makrigiorgos, et al., "Inhomogeneous Deposition of Radiopharmaceuticals at the Cellular Level: Experimental Evidence and Dosimetric Implications", J.Nucl.Med., 31:1358-1363, 1990	
	A15	Mostafavi et al,"Synthesis, Purification and Biological Activity of (SER10-Phosphatidyl)-Urotilatin (Phosphourotilatin), Biomed. Pept. Proteins Nucleic Acids 1: 255-60, 1995	
	A16	Mullinax, et al., "Identification of human antibody fragment clones specific for tetanus toxoid in a bacteriophage lambda immunorepression library", Proc. Natl. Acad. Sci., 87:8095-8099, 1990	
	A17	Riechmann, et al., "Reshaping Human Antibodies for Therapy", Nature 332:323, 1988	
	A18	Scott and Smith, "Searching for Peptide Ligands with an Epitope Library", Science 249, 386-88, 1990	
	A19	Shaw, et al., "Characterization of a Mouse/Human Chimeric Monoclonal Antibody (17-1A) to a Colon Cancer Tumor-Associated Antigen", J. Immun., 138:4534 (1987	
	A20	Sheng, et al., "Cardiotrophin 1 (CT-1) Inhibition of Cardiac Myocyte Apoptosis Via A Mitogen=activated Protein Kinase-dependent Pathway", J.Biol. Chem., 272:5783-5791 (1997	

Examiner
Signature

/D. Jones/

Date

Considered

11/25/09

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DLMR_298797.1

ALL REFERENCES CONSIDERED. /DJ/

PTO/SB/08 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	10/591,092
Filing Date	08-29-2006
First Named Inventor	Kirk Knowlton
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	041673-0206

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A21	Spira, et al., "The Identification of Monoclonal Class Switch Variants by Sib Selection and an ELISA Assay", <i>J. Immunol. Methods</i> , 74 :307, 1984	
	A22	Sun, L.K., et al., "Chimeric Antibody With Human Constant Regions and Mouse Variable Regions Directed Against Carcinoma-Associated Antigen 17-1A", <i>Proc. Natl. Acad. Sci. USA</i> , 84 :214-218 (1987)	
	A23	Stepleski, et al., "Isolation and Characterization of Anti-monoisialoganglioside Monoclonal Antibody 19-9 Class-Switch Variants", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 82 :8653, 1985	
	A24	Ward et al., "Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from <i>Escherichia Coli</i> ", (1989) <i>Nature</i> 341:544-546)	
	A25	Wilson et al., "Simplified Conjugation Chemistry for Coupling Peptides to F(ab') Fragments: Autologous Red Cell Agglutination Assay for HIV-1 Antibodies", (1994) <i>J. Immunol. Methods</i> 175:267-273	
	A26	Yarmush M.L., et al., "Coupling of Antibody-Binding Fragments to Solid-Phase Supports: Site-Directed Binding of F(ab') ₂ Fragments", (1992) <i>J. Biochem. Biophys. Methods</i> 25:85-97	

Examiner
Signature

/D. Jones/

Date
Considered

11/25/09

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DLMR_298797.1

ALL REFERENCES CONSIDERED. /DJ/